Dyslipidemias
Recent clinical, regulatory, research and industry developments relating to this disease.
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
The Association between Dyslipidemia and Pulmonary Diseases.
Intermittent Fasting Regulates Metabolic Homeostasis and Improves Cardiovascular Health.
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia.
Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
The gut microbiome and metabolic syndrome.
Association between insulin resistance and the development of cardiovascular disease.
Psoriasis and comorbid diseases: Epidemiology.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study
- Q4 2026Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia
- Q2 2027A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias
- Q1 2028Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Clinical MilestonesView all 9Hide
- 2025-10-08A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk FactorsResults posted
- 2025-09-19A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying TherapiesResults posted
- 2026-05-22A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory DyslipidemiasResults expected Q2 2027
- 2026-05-05Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined DyslipidemiaResults expected Q4 2026
- 2026-04-09A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT StudyResults expected Q4 2026
- 2025-12-17Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)Results expected Q1 2028
- 2027-12-01ClinicalEvaluate Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A in Mixed Dyslipidemia PatientsWithdrawn
- 2026-05-31ClinicalA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed DyslipidemiaPrimary completion
- 2026-05-22ClinicalA Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory DyslipidemiasResults expected Q2 2027
- 2026-05-05ClinicalEffect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined DyslipidemiaResults expected Q4 2026
- 2026-04-09ClinicalA Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT StudyResults expected Q4 2026
- 2025-12-17ClinicalCholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)Results expected Q1 2028
- 2025-10-08ClinicalA Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk FactorsResults posted
- 2025-09-24ClinicalEffect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)Completed
- 2025-09-19ClinicalA Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying TherapiesResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Dyslipidemias3
- Cardiovascular Diseases2
- COVID-191
- Diabetes Mellitus, Type 21
- Dietary Supplements1
- Fasting1
- Gastrointestinal Microbiome1
- Homeostasis1
Leading journals6
- European heart journal2
- Arteriosclerosis, thrombosis, and vascular biology1
- Cardiovascular diabetology1
- Cell biochemistry and biophysics1
- Cells1
- Journal of atherosclerosis and thrombosis1
Leading researchers8
- Catapano AL2
- Chapman MJ2
- Riccardi G2
- Taskinen MR2
- Wiklund O2
- Agewall S1
- Aguayo C1
- Alegria E1
Affiliations (unnormalised)6
- American University of Beirut Medical Center1
- Brigham and Women's Hospital1
- Cedars-Sinai Medical Center1
- Center for Clinical Epidemiology and Biostatistics1
- College of Medicine1
- Department of Clinical Biochemistry and Immunology1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Dyslipidemias are abnormalities in serum lipid levels, including excess or deficiency of circulating lipids. They may present as elevated total cholesterol, elevated triglycerides, low high-density lipoprotein cholesterol, or elevated low-density lipoprotein cholesterol.
The supplied grounding supports lifestyle-related contributors, including dietary habits and lack of physical activity. It also supports associations with insulin resistance, obesity, type 2 diabetes, and altered gut microbiome-related metabolic regulation.
The literature grounding links dyslipidemia to disturbed lipid metabolism and to atherogenic lipid patterns such as hypertriglyceridemia, increased small dense LDL particles, and reduced HDL cholesterol. Shared metabolic pathways mentioned in the grounding include inflammation, endoplasmic reticulum stress, oxidative stress, ectopic lipid deposition, and altered bile acid and microbial metabolite signaling.
Supported risk factors include unhealthy dietary habits, physical inactivity, obesity, insulin resistance, and type 2 diabetes. The grounding also identifies age and male sex as non-modifiable cardiovascular risk factors in the broader context in which dyslipidemia is managed.
Management is described at the level of lifestyle intervention and pharmacologic lipid-lowering therapy. The grounding supports diet, exercise, and dietary supplements as non-drug approaches, alongside treatment strategies aimed at correcting abnormal lipid profiles and reducing cardiovascular risk.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.